Steven A. Feldman, Ph.D.
Staff Scientist
Director, Surgery Branch Vector Production Facility
Chair, NIH Institutional Biosafety Committee

Center for Cancer Research
National Cancer Institute

Building 10 - Magnuson ACRF, Room 1B37A
Bethesda, MD 20892-1201
301-496-4269

Dr. Feldman directs the Surgery Branch Vector Production Facility, which develops and manufactures cGMP quality retroviral and lentiviral vectors for the ex vivo genetic modification of T lymphocytes in support of the Branch’s clinical efforts utilizing adoptive cell transfer for the treatment of patients with cancer including melanoma, sarcomas and lymphomas. Dr. Feldman’s research interests include development of retroviral and lentiviral packaging cell lines and novel strategies for the large-scale closed cell culture processes to support production of clinical reagents. In addition, the lab is focused on identifying novel tumor-associated antigens and developing T cell receptors and chimeric antigen receptors to re-direct T cells to target specific tumors.

Areas of Expertise
immunotherapy, gene therapy, adoptive cell therapy, viral vector development, cell line development, cGMP manufacturing

The NCI Surgery Branch Vector Production Facility is charged with producing clinical grade retroviral vectors in support of our clinical trials. The majority of patients with advanced metastatic cancer now enrolled in clinical trials in the Surgery Branch have failed conventional and most experimental treatments including chemotherapy, high-dose IL-2 treatment, vaccination with tumor antigen peptides and recombinant viruses that encode tumor antigens, as well as adoptive transfer of autologous tumor reactive T cells. Overall, despite all of these intensive treatment options, durable responses have only been observed in a limited number of patients, demonstrating the urgent need for the development of new and more effective cancer treatments. The clinical reagents produced in the Surgery Branch Vector Production Facility will be used for expressing anti-cancer genes within immune cells for use in cancer immunotherapy trials. These trials will allow the evaluation of the effectiveness of genetically engineered human T lymphocytes and other cells of the immune system to express anti-cancer genes and cause tumor regression in patients enrolled in our cancer immunotherapy trials.

Selected Publications
  1. Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN, Steinberg SM, Stroncek D, Tschernia N, Yuan C, Zhang H, Zhang L, Rosenberg SA, Wayne AS, Mackall CL
    The Lancet. 385(9967): 517-528, 2015. [ Journal Article ]
  2. Robbins PF, Kassim SH, Tran TL, Crystal JS, Morgan RA, Feldman SA, Yang JC, Dudley ME, Wunderlich JR, Sherry RM, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, Li YF, El-Gamil M, Rosenberg SA
    Clin. Cancer Res.. 21(5): 1019-1027, 2015. [ Journal Article ]
  3. Yang S, Karne NK, Goff SL, Black MA, Xu H, Bischof D, Cornetta K, Rosenberg SA, Morgan RA, Feldman SA
    Hum Gene Ther. Methods. 23(2): 73-83, 2012. [ Journal Article ]
  4. Feldman SA, Goff SL, Xu H, Black MA, Kochenderfer JN, Johnson LA, Yang JC, Wang Q, Parkhurst MR, Cross S, Morgan RA, Cornetta K, Rosenberg SA
    Hum Gene Ther.. 22(1): 107-115, 2011. [ Journal Article ]
  5. Abate-Daga D, Speiser DE, Chinnasamy N, Zheng Z, Xu H, Feldman SA, Rosenberg SA, Morgan RA.
    PLoS ONE. 9(3): e93321, 2014. [ Journal Article ]

Dr. Feldman received his B.A., M.P.H., and Ph.D. from University of California, Berkeley. As a National Reseach Council fellow, he studied mechanisms of viral entry at the FDA's Centers for Biologics Evaluation and Research followed by an addtional NIH fellowhsip investigating the mechanisms of retroviral entry into host cells. Dr. Feldman then spent three years at a leading biotechnology company as the Senior Scientist in charge of process development for the manufacturing of viral vectors and vaccines before coming back to the Surgery Branch of the National Cancer Institute to establish a new Retro/Lentiviral Vector Core Facility.

Name Position
Yasmine Assadipour M.D. Clinical Fellow
Mary Black Research Biologist
Harshini Chinnasamy Postbaccalaureate Fellow
Isaac Kriley M.D. Clinical Fellow
Hui Xu Research Biologist

Summary

Dr. Feldman directs the Surgery Branch Vector Production Facility, which develops and manufactures cGMP quality retroviral and lentiviral vectors for the ex vivo genetic modification of T lymphocytes in support of the Branch’s clinical efforts utilizing adoptive cell transfer for the treatment of patients with cancer including melanoma, sarcomas and lymphomas. Dr. Feldman’s research interests include development of retroviral and lentiviral packaging cell lines and novel strategies for the large-scale closed cell culture processes to support production of clinical reagents. In addition, the lab is focused on identifying novel tumor-associated antigens and developing T cell receptors and chimeric antigen receptors to re-direct T cells to target specific tumors.

Areas of Expertise
immunotherapy, gene therapy, adoptive cell therapy, viral vector development, cell line development, cGMP manufacturing

Research

The NCI Surgery Branch Vector Production Facility is charged with producing clinical grade retroviral vectors in support of our clinical trials. The majority of patients with advanced metastatic cancer now enrolled in clinical trials in the Surgery Branch have failed conventional and most experimental treatments including chemotherapy, high-dose IL-2 treatment, vaccination with tumor antigen peptides and recombinant viruses that encode tumor antigens, as well as adoptive transfer of autologous tumor reactive T cells. Overall, despite all of these intensive treatment options, durable responses have only been observed in a limited number of patients, demonstrating the urgent need for the development of new and more effective cancer treatments. The clinical reagents produced in the Surgery Branch Vector Production Facility will be used for expressing anti-cancer genes within immune cells for use in cancer immunotherapy trials. These trials will allow the evaluation of the effectiveness of genetically engineered human T lymphocytes and other cells of the immune system to express anti-cancer genes and cause tumor regression in patients enrolled in our cancer immunotherapy trials.

Publications

Selected Publications
  1. Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN, Steinberg SM, Stroncek D, Tschernia N, Yuan C, Zhang H, Zhang L, Rosenberg SA, Wayne AS, Mackall CL
    The Lancet. 385(9967): 517-528, 2015. [ Journal Article ]
  2. Robbins PF, Kassim SH, Tran TL, Crystal JS, Morgan RA, Feldman SA, Yang JC, Dudley ME, Wunderlich JR, Sherry RM, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, Li YF, El-Gamil M, Rosenberg SA
    Clin. Cancer Res.. 21(5): 1019-1027, 2015. [ Journal Article ]
  3. Yang S, Karne NK, Goff SL, Black MA, Xu H, Bischof D, Cornetta K, Rosenberg SA, Morgan RA, Feldman SA
    Hum Gene Ther. Methods. 23(2): 73-83, 2012. [ Journal Article ]
  4. Feldman SA, Goff SL, Xu H, Black MA, Kochenderfer JN, Johnson LA, Yang JC, Wang Q, Parkhurst MR, Cross S, Morgan RA, Cornetta K, Rosenberg SA
    Hum Gene Ther.. 22(1): 107-115, 2011. [ Journal Article ]
  5. Abate-Daga D, Speiser DE, Chinnasamy N, Zheng Z, Xu H, Feldman SA, Rosenberg SA, Morgan RA.
    PLoS ONE. 9(3): e93321, 2014. [ Journal Article ]

Biography

Dr. Feldman received his B.A., M.P.H., and Ph.D. from University of California, Berkeley. As a National Reseach Council fellow, he studied mechanisms of viral entry at the FDA's Centers for Biologics Evaluation and Research followed by an addtional NIH fellowhsip investigating the mechanisms of retroviral entry into host cells. Dr. Feldman then spent three years at a leading biotechnology company as the Senior Scientist in charge of process development for the manufacturing of viral vectors and vaccines before coming back to the Surgery Branch of the National Cancer Institute to establish a new Retro/Lentiviral Vector Core Facility.

Team

Name Position
Yasmine Assadipour M.D. Clinical Fellow
Mary Black Research Biologist
Harshini Chinnasamy Postbaccalaureate Fellow
Isaac Kriley M.D. Clinical Fellow
Hui Xu Research Biologist